Allogenic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia

2013

Warren Sanger
[email protected]
402-559-6328

Philadelphia chromosome-positive acute myeloid (Ph-AML) for approximately 1% of all cases of AML. The few publications available on the treatment and outcome of Ph-AML patients suggest a poor response to anthracycline and cytarabine containing regimens, a high relapse rate and a dismal prognosis. Although several therapy options including imatinib and allogeneic stem cell transplantation (allo-SCT) are promising, relatively short follow-up limits our understanding of long-term results of these therapies. In this report, we describe the outcomes of three cases of Ph-AML, diagnosed and transplante at the University of Nebraska Medical Center between 2004-2011. These patients, young and without major comorbidities, received induction therapy with 7 days of cytarabine and 3 days of idarubicin along with imatinib and consolidation thereapy with high dose cytarabine (with or without imatinib). All patients underwent 10/10 human leukocyte antigen-matched peripheral blood allo-SCT.

Leukemia, Transplantation

Peer-reviewed publications in scholarly journals submitted

Professionals

N/A